Rodrigues, Felipe FernandesBraz, Wilson RodriguesPerasoli, Fernanda BarçanteFerreira, Letícia Gonçalves ResendeBarbosa, Leandro Augusto de OliveiraSilva, Gisele Rodrigues da2019-04-172019-04-172017RODRIGUES, F. F. et al. Implants composed of digoxin and poly(ε-caprolactone) : development, characterization, anti-proliferative and anti-angiogenic activities. Pharmazie, v. 72, n. 7, p. 383–388, 2017. Disponível em: <https://www.ingentaconnect.com/contentone/govi/pharmaz/2017/00000072/00000007/art00002>. Acesso em: 25 fev. 2019.0031-7144http://www.repositorio.ufop.br/handle/123456789/11059Drug delivery systems could be applied to locally treat cervical cancer, thus preventing the drawbacks of conventional therapy. In this study, anti-proliferative and anti-angiogenic effects of digoxin incorporated into poly(ε-caprolactone) implants were evaluated, aiming at the local treatment of cervical cancer. Implants were characterized, and the in vitro release profile of digoxin was demonstrated. Anti-proliferative and anti-angiogenic activities of digoxin were investigated by using chorioallantoic membrane and human cervix carcinoma (HeLa) cells, respectively. The chemical structure of digoxin and the semi-crystalline nature of poly(ε-caprolactone) were preserved after designing implants. The hydrophobicity of drug and polymer as well as the semi-crystalline structure provided a controlled diffusion of digoxin from implants. Digoxin released from implantable devices exhibited anti-proliferative activity against HeLa cells. The anti-angiogenic effect was also shown. Finally, implants composed of digoxin and poly(ε-caprolactone) could be applied as a therapeutic alternative to treat the early stage of cervical cancer, once they were able to locally control the release of this anti-angiogenic and anti-proliferative drug, minimizing its systemic side effects and toxicity.en-USrestritoArtigo publicado em periodicohttps://www.ingentaconnect.com/contentone/govi/pharmaz/2017/00000072/00000007/art00002